Skip to main content

Table 4 Major results of health economic assessment of SBRT in the treatment of HCC

From: Health economic evaluation of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma: a systematic review

Included researchIntervention techniqueControl techniqueIncremental costIncremental outputICERPayment thresholdBasic conclusion
Hayeon Kim [17]SBRTcRFAd82020.050164,660100,000aNot cost-effective
Leung [18]SorafenibSBRT969,0410.2603788,2382213,145bNot cost-effective
Pollom [19]SBRT–SBRTRFA-SBRT42690.008558,679100,000aNot cost-effective
SBRT–RFARFA–SBRT4,3940.0022197,000100,000aNot cost-effective
RFA–RFARFA–SBRT283− 0.012100,000aDominated
Leung [20]Proton beam therapySBRT557,9072.610213,3542157,024bCost-effective
Parikh [21]SBRTRFA− 1967− 0.03556,301100,000aNot cost-effective
  1. a The cost unit of incremental cost, ICER, and threshold value were in US dollars; b The cost unit of incremental cost, ICER, and threshold value were in New Taiwan dollars; c stereotactic body radiotherapy; d radiofrequency ablation; % ICER per life-year gained, not quality life-year gained